Prognostic Value of Prothrombin Fragments 1+2 for Pulmonary Embolism Incidence

Overview

To determine the possible association of prothrombin fragments 1+2 elevation with incidents of pulmonary embolism in patients with COPD exacerbation.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective

Interventions

  • Other: CT pulmonary angio, blood tests

Arms, Groups and Cohorts

  • COPD exacerbation
    • Patients admitted to hospital with COPD exacerbation

Participating in This Clinical Trial

Inclusion Criteria

  • COPD exacerbation – Able to give informed consent – Able to perform spirometry Exclusion Criteria:

  • Known malignancy – Known hypercoagulable state – Receiving anticoagulant treatment – Pregnancy – Renal failure – Allergy to Iodine

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hillel Yaffe Medical Center
  • Provider of Information About this Clinical Study
    • Marinella Beckerman, Hillel Yaffe Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.